Response definitions and European Leukemianet Management recommendations.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedBiomarkers for determining the prognosis in chronic myelogenous leukemiaInterpreting molecular monitoring results and international standardization in chronic myeloid leukemia.Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar.Implementation of management guidelines for chronic myeloid leukemia: perspectives in the United States.Best Practices in Chronic Myeloid Leukemia Monitoring and ManagementIssues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcomeDevelopment of an effective therapy for chronic myelogenous leukemiaBCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Insights on practice variations in the management of lymphoma and leukemia.Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.CAMKIIγ, HSP70 and HSP90 transcripts are differentially expressed in chronic myeloid leukemia cells from patients with resistant mutated disease.Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia.BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.Imatinib mesylate resistance and mutations: An Indian experienceA single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.cDNA synthesis for BCR-ABL1 detection at the MMR level: the importance of using the appropriate kit.KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response.Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors.Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia
P2860
Q26738514-B40BE86A-CA5A-459D-AB80-30189D9DD210Q26824660-4A84FF35-05C5-4899-838B-F86265313855Q33885583-9D4E0044-8FF1-426F-B1BD-6D9D66BA9F70Q36331689-C9D2B4D0-9C62-4818-B2E8-2C7F2B497880Q36401763-B67B6FC9-D024-4312-A544-B3AA5B0C22B6Q36884361-F78DFBF8-F194-4A81-AF56-ECC4B7183617Q37422287-D94CDC3E-74FD-4477-97C5-D4FE8FAABC30Q37966917-3B10989E-1267-436E-AB71-4F25FFD3F594Q37974490-B0B3D391-65D5-4E76-B249-D49724E94C9DQ37988569-51E20872-89F1-4593-A602-98A8AF358958Q38177354-A0E8DD37-57A6-47C4-A640-B10BF177783CQ38991152-DA28A9C6-C447-4253-A37C-90480C8EF8E0Q39065654-71C03102-66E4-44F6-BA47-4A20ED4F239CQ39779762-C51C36AB-FDDD-4CE3-AAF5-11481C40C9D4Q41470558-F281D0DC-B75E-4C25-8F7F-14F198D4DE9AQ41892319-2D2BCD37-8451-47FF-B4BC-862884166F4CQ41912896-6941B032-3DF4-4425-82AA-FD1E10366BF1Q42128429-5FF61990-3499-48C5-9353-684871445D19Q44893639-A9354070-0072-45D3-A80F-47953467EC81Q46321468-EECF176D-4A86-45DE-B989-3F6AB1518432Q46573433-56463B2F-B118-4A7B-95F7-19DC60521F43Q53136807-3D6B1E3E-5E6E-4DC8-8EC9-E7464E489225Q54117334-0F862C80-8260-4D41-B358-A58A0BED5AB6Q54222903-1F92183D-B8ED-49FA-B847-CD76A7D7E60DQ54357380-B0474726-6443-40C0-81AD-3EC93542E8B3Q56973578-8A7E7CA3-8101-4FB4-8EC0-762CA1FCB960
P2860
Response definitions and European Leukemianet Management recommendations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Response definitions and European Leukemianet Management recommendations.
@en
Response definitions and European Leukemianet Management recommendations.
@nl
type
label
Response definitions and European Leukemianet Management recommendations.
@en
Response definitions and European Leukemianet Management recommendations.
@nl
prefLabel
Response definitions and European Leukemianet Management recommendations.
@en
Response definitions and European Leukemianet Management recommendations.
@nl
P50
P1476
Response definitions and European Leukemianet Management recommendations.
@en
P2093
European Leukemia Net
P304
P356
10.1016/J.BEHA.2009.10.001
P577
2009-09-01T00:00:00Z